Page 1 | Search Results | Blood | American Society of Hematology

1-14 of 14

Sort by

Sort Order Select

Journal Articles

Perspectives on drug development in chronic myelomonocytic leukemia: changing the paradigm

Anthony M. Hunter, Mrinal M. Patnaik, Raphael Itzykson, Ruben Mesa, Chatchada Karanes, Yanxia Li, R. Angelo de Claro, Kelly J. Norsworthy, Marc Theoret, Elizabeth Pulte, Eric Padron

Blood (2024) 144 (19): 1987–1992.

https://doi.org/10.1182/blood.2024025648

Published: 2024

Journal Articles

FDA Analysis of Race and Ethnic Enrollment of Clinical Trials for Drug Registration in Adult Patients for Leukemia and Myelodysplastic Syndrome

Ashley C. Woods, Dianne D. Pulte, Kamar Godder, Emily Jen, Nina Kim, Robert Le, Catherine C. Lerro, Donna Rivera, Gulsum Pamuk, Nicole J. Gormley, Marc R. Theoret, Kelly J. Norsworthy, R. Angelo De Claro

Blood (2024) 144 (Supplement 1): 3806.

https://doi.org/10.1182/blood-2024-204164

Published: 2024

Journal Articles

Response Rate, Event-Free Survival (EFS), and Overall Survival in Higher-Risk Myelodysplastic Syndromes (MDS): U.S. Food and Drug Administration (FDA) Trial-Level and Patient-Level Analyses

Nina Kim, Xin Wang, Ilynn Bulatao, Jonathon Vallejo, Yuan Li Shen, Dianne D. Pulte, Marc R. Theoret, R. Angelo De Claro, Kelly J. Norsworthy

Blood (2024) 144 (Supplement 1): 1829.

https://doi.org/10.1182/blood-2024-208514

Published: 2024

Journal Articles

Real-World Treatment Patterns Among Patients with Newly-Diagnosed (ND)-Acute Myeloid Leukemia (AML) in the United States (US)

Dianne Pulte, Kelly J. Norsworthy, Laura Fernandes, Bindu Kanapuru, Catherine Lerro, Fatima Rizvi, Jonathon Vallejo, Kun Wang, Joseph Wynne, Anna Barcellos, Andrew J. Belli, Eric Hansen, Thomas Gwise, Paul Kluetz, Angelo De Claro, Ching-Kun Wang, Donna Rivera

Blood (2022) 140 (Supplement 1): 5100–5102.

https://doi.org/10.1182/blood-2022-169054

Published: 2022

Journal Articles

Response Rate, Event-Free Survival (EFS) and Overall Survival (OS) in Higher-Risk Myelodysplastic Syndromes (HR-MDS): U.S. Food and Drug Administration (FDA) Patient-Level Analyses

Nina Kim, Jonathon Vallejo, Jonathan Herz, Thomas Gwise, R. Angelo de Claro, Marc Theoret, Richard Pazdur, Kelly J. Norsworthy

Blood (2021) 138 (Supplement 1): 2604.

https://doi.org/10.1182/blood-2021-147558

Published: 2021

Journal Articles

Response Prediction to Isocitrate Dehydrogenase (IDH) Inhibitors in Patients with IDH1 - or IDH2 -Mutated Acute Myeloid Leukemia Using Clinical and Genomic Data

Blood (2021) 138 (Supplement 1): 1285.

https://doi.org/10.1182/blood-2021-147099

Published: 2021

Journal Articles

FDA Analysis of Screen Failures By Race in Clinical Trials of Acute Myeloid Leukemia

Dianne Pulte, MD, Guo Wei, Kelly J. Norsworthy, MD, Yutao Gong, PhD, Nicole J. Gormley, MD, Bindu Kanapuru, MD, Richard Pazdur, MD, Julie Schneider, Marc Theoret, MD, Angelo De Claro, MD

Blood (2020) 136 (Supplement 1): 23–24.

https://doi.org/10.1182/blood-2020-136363

Published: 2020

Journal Articles

Second Cancers in Adults with Acute Promyelocytic Leukemia (APL) Treated with or without Arsenic Trioxide (ATO): A SEER-Medicare Analysis

Kelly J. Norsworthy, MD, Steven T. Bird, PhD PharmD, MS, Armen Avagyan, MS, Yuchen Li, MS, Sandia Akhtar, BS, Jiemin Liao, MA, Michael Wernecke, BA, Albert B. Deisseroth, MD PhD, Meredith Chuk, MD, Thomas E. MaCurdy, PhD, Richard Swain, PhD, Jeffrey A. Kelman, MD MMSc, Ann T. Farrell, MD, Richard Pazdur, MD, Gideon Blumenthal, MD, David J. Graham, MD MPH

Blood (2019) 134 (Supplement_1): 3497.

https://doi.org/10.1182/blood-2019-130295

Published: 2019

Journal Articles

Incidence of Differentiation Syndrome with Ivosidenib (IVO) and Enasidenib (ENA) for Treatment of Patients with Relapsed or Refractory (R/R) Isocitrate Dehydrogenase (IDH)1- or IDH2-Mutated Acute Myeloid Leukemia (AML): A Systematic Analysis By the U.S. Food and Drug Administration (FDA)

Kelly J. Norsworthy, MD, Flora Mulkey, MS, Ashley F. Ward, MD, Donna Przepiorka, MDPhD, Albert B. Deisseroth, MD PhD, Ann T. Farrell, MD, Richard Pazdur, MD

Blood (2018) 132 (Supplement 1): 288.

https://doi.org/10.1182/blood-2018-99-117426

Published: 2018

Journal Articles

Response Rate, Event-Free Survival (EFS), and Overall Survival (OS) in Newly-Diagnosed Acute Myeloid Leukemia (AML): U.S. Food and Drug Administration (FDA) Trial-Level and Patient-Level Analyses

Kelly J. Norsworthy, MD, Xin Gao, PhD, Chia-Wen Ko, PhD, Jiaxi Zhou, MS, Yutao Gong, PhD, Yuan Li Shen, PhD, Rajeshwari Sridhara, PhD, Albert B. Deisseroth, MD PhD, Ann T. Farrell, MD, Richard Pazdur, MD, Gideon Blumenthal, MD

Blood (2018) 132 (Supplement 1): 2670.

https://doi.org/10.1182/blood-2018-99-119678

Published: 2018

Journal Articles

Developing a Genomics Model to Predict Failure of Isocitrate Dehydrogenase (IDH) Inhibitors for Treatment of Patients with IDH1- or IDH2-Mutated Acute Myeloid Leukemia

Tigran Ghazanchyan, MS, Dickran Kazandjian, MD, Donna Przepiorka, MD PhD, Kelly J. Norsworthy, MD, Emma Scott, PhD, Luis Santana-Quintero, PhD, Svetlana Petrovskaya, PhD, Yong Zhang, PhD, Amy Rosenberg, MD, Ashutosh Rao, PhD, Richard Pazdur, MD, Ann T. Farrell, MD, Julia A. Beaver, MD, Vahan Simonyan, PhD

Blood (2018) 132 (Supplement 1): 2815.

https://doi.org/10.1182/blood-2018-99-116870

Published: 2018

Journal Articles

The Cell of Origin in NPM1 Positive Acute Myeloid Leukemia (AML) Is Prognostic

Mark Iscoe, BA, Kelly J Norsworthy, MD, Gabriel Ghiaur, MD PhD, B. Douglas Smith, Christopher Gocke, MD, Richard J Jones, MD

Blood (2016) 128 (22): 1690.

https://doi.org/10.1182/blood.V128.22.1690.1690

Published: 2016

Journal Articles

RAR-Alpha Targeting Compounds Overcome Bone Marrow (BM) Stromal Protection of AML By CYP26

Kelly J Norsworthy, MD, Daniela Hernandez, MD, Meng Su, BS, Megan E McCray, BA, Christopher A Esteb, BS, Roshantha A Chandraratna, PhD, B. Douglas Smith, MD, Richard J Jones, MD, Gabriel Ghiaur, MD PhD

Blood (2015) 126 (23): 2474.

https://doi.org/10.1182/blood.V126.23.2474.2474

Published: 2015

Journal Articles

Phase 1 Study of UCN-01 in Combination with Perifosine in Patients with Relapsed and Refractory Acute Leukemias and High Risk Myelodysplastic Syndromes (MDS)

Kelly J. Norsworthy, MD, Alexander E Perl, MD, Martin Carroll, MD, Selina M. Luger, MD, Kenneth S. Bauer, PharmD, PhD, Michael L. Tidwell, CRNP, Dina Ioffe, BA, Maria R. Baer, MD, Edward A. Sausville, MD, PhD, Ivana Gojo, MD

Blood (2011) 118 (21): 1557.

https://doi.org/10.1182/blood.V118.21.1557.1557

Published: 2011

NARROW

Perspectives on drug development in chronic myelomonocytic leukemia: changing the paradigm

FDA Analysis of Race and Ethnic Enrollment of Clinical Trials for Drug Registration in Adult Patients for Leukemia and Myelodysplastic Syndrome

Response Rate, Event-Free Survival (EFS), and Overall Survival in Higher-Risk Myelodysplastic Syndromes (MDS): U.S. Food and Drug Administration (FDA) Trial-Level and Patient-Level Analyses

Real-World Treatment Patterns Among Patients with Newly-Diagnosed (ND)-Acute Myeloid Leukemia (AML) in the United States (US)

Response Rate, Event-Free Survival (EFS) and Overall Survival (OS) in Higher-Risk Myelodysplastic Syndromes (HR-MDS): U.S. Food and Drug Administration (FDA) Patient-Level Analyses

Response Prediction to Isocitrate Dehydrogenase (IDH) Inhibitors in Patients with IDH1 - or IDH2 -Mutated Acute Myeloid Leukemia Using Clinical and Genomic Data

FDA Analysis of Screen Failures By Race in Clinical Trials of Acute Myeloid Leukemia

Second Cancers in Adults with Acute Promyelocytic Leukemia (APL) Treated with or without Arsenic Trioxide (ATO): A SEER-Medicare Analysis

Incidence of Differentiation Syndrome with Ivosidenib (IVO) and Enasidenib (ENA) for Treatment of Patients with Relapsed or Refractory (R/R) Isocitrate Dehydrogenase (IDH)1- or IDH2-Mutated Acute Myeloid Leukemia (AML): A Systematic Analysis By the U.S. Food and Drug Administration (FDA)

Response Rate, Event-Free Survival (EFS), and Overall Survival (OS) in Newly-Diagnosed Acute Myeloid Leukemia (AML): U.S. Food and Drug Administration (FDA) Trial-Level and Patient-Level Analyses

Developing a Genomics Model to Predict Failure of Isocitrate Dehydrogenase (IDH) Inhibitors for Treatment of Patients with IDH1- or IDH2-Mutated Acute Myeloid Leukemia

The Cell of Origin in NPM1 Positive Acute Myeloid Leukemia (AML) Is Prognostic

RAR-Alpha Targeting Compounds Overcome Bone Marrow (BM) Stromal Protection of AML By CYP26

Phase 1 Study of UCN-01 in Combination with Perifosine in Patients with Relapsed and Refractory Acute Leukemias and High Risk Myelodysplastic Syndromes (MDS)

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only